Skip to content
2000
Volume 16, Issue 5
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

In spite of advances in tuberculosis (TB) chemotherapy, TB is still airborne deadly disorder as a major issue of health concern worldwide today. Extensive researches have been focused to develop novel drug delivery systems to shorten the lengthy therapy approaches, prevention of relapses, reducing dose-related toxicities and to rectify technologically related drawbacks of anti-tubercular drugs. Moreover, the rapid emergence of drug resistance, poor patient compliance due to negative therapeutic outcomes and intracellular survival of Mycobacterium highlighted to develop carrier with optimum effectiveness of the anti-tubercular drugs. This could be achieved by targeting and concentrating the drug on the infection reservoir of Mycobacterium. In this article, we briefly compiled the general aspects of Mycobacterium pathogenesis, disease treatment along with progressive updates in novel drug delivery carrier system to enhance therapeutic effects of drug and the high level of patient compliance. Recently developed several vaccines might be shortly available as reported by WHO.

Loading

Article metrics loading...

/content/journals/cdd/10.2174/1567201816666190201144815
2019-06-01
2025-05-03
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/1567201816666190201144815
Loading

  • Article Type:
    Review Article
Keyword(s): Clinical therapy; diagnosis; nanomedicine; pathogenesis; review; Tuberculosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test